Compare NBIX & COKE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NBIX | COKE |
|---|---|---|
| Founded | 1992 | 1902 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Beverages (Production/Distribution) |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.2B | 13.4B |
| IPO Year | 1996 | 1994 |
| Metric | NBIX | COKE |
|---|---|---|
| Price | $163.88 | $179.91 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 22 | 0 |
| Target Price | ★ $180.91 | N/A |
| AVG Volume (30 Days) | ★ 1.1M | 649.0K |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 0.50% |
| EPS Growth | 41.95 | ★ 156.81 |
| EPS | ★ 1.91 | 1.21 |
| Revenue | $161,626,000.00 | ★ $7,228,055,000.00 |
| Revenue This Year | $24.73 | N/A |
| Revenue Next Year | $13.14 | N/A |
| P/E Ratio | ★ $87.58 | $140.41 |
| Revenue Growth | ★ 977.51 | 4.76 |
| 52 Week Low | $122.14 | $105.44 |
| 52 Week High | $169.57 | $218.73 |
| Indicator | NBIX | COKE |
|---|---|---|
| Relative Strength Index (RSI) | 65.15 | 51.27 |
| Support Level | $134.92 | $180.44 |
| Resistance Level | N/A | $182.49 |
| Average True Range (ATR) | 4.51 | 6.77 |
| MACD | 0.13 | 1.06 |
| Stochastic Oscillator | 67.18 | 83.37 |
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.
Coca-Cola Consolidated Inc distributes, markets, and manufactures nonalcoholic beverages. It offers a range of nonalcoholic beverage products and flavors, including both sparkling and still beverages. Sparkling beverages are carbonated beverages, and the Company's principal sparkling beverage is Coca-Cola. Still beverages include energy products and non-carbonated beverages such as bottled water, ready-to-drink tea, ready-to-drink coffee, enhanced water, juices, and sports drinks. The Company has two operating segments: Nonalcoholic Beverages and All Other. Key revenue is generated from Nonalcoholic Beverages.